Table 1.
Characteristics of included studies in this network meta-analysis.
| First author | Year | Country/district | Study period | Number of patients | Cancer types | ICD | Research types | Statin types | Quality of scores |
|---|---|---|---|---|---|---|---|---|---|
| Chen [34] | 2015 | Taiwan | 2000–2010 | 2053 | Hepatocellular carcinoma | ICD-9-CN: 155 | Case-control study | a, b, c, d, e, f | 8/9 |
| El–Serag [35] | 2009 | United States | 1997–2002 | 3302 | Hepatocellular carcinoma | ICD-9-CM: 155 | Case-control study | a | 8/9 |
| Lee [37] | 2012 | Korea | 1999–2008 | 1920 | Gastric cancer | ICD: 16.0–16.9 | Case-control study | a, b, c, f, g | 8/9 |
| Beishuizen [36] | 2004 | Netherlands | 2001–2003 | 182 | Malignancies | / | RCT | a | 5 |
| Wanner [38] | 2005 | Germany | 1998–2004 | 1255 | Cancer | / | RCT | b | 5 |
| Kim [39] | 2016 | Korea | 2002–2013 | 154 | Hepatocellular carcinoma | ICD C22.0 | Case-control study | a, b, c, d, e, f, g | 8/9 |
| Hachem [40] | 2009 | United States | 1997–2002 | 14,707 | Colorectal cancer | ICD-9: 153.0–153.9154.0–154.1154.8230.3230.4 | Case-control study | a | 8/9 |
RCT: randomized controlled trial; /: there is no record of the ICD of cancer; ICD: international classification of disease; a: simvastatin; b: atorvastatin; c: pravastatin; d: fluvastatin; e: lovastatin; f: rosuvastatin, g: pitavastatin.